Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Novartis Drug Reduces Disability Progression Risk in Rare Form of MS

By Ryan Bushey | September 20, 2016

Novartis could have a strong contender in treating a rare form of multiple sclerosis.

The Swiss drug maker posted updated data over the weekend for its investigational treatment BAF312  in which the data demonstrated the drug could lower the risk of disability progression in patients diagnosed with secondary progressive multiple sclerosis.

BAF312 was able to reduce the risk of three-month confirmed disability progression by 21 percent when compared to placebo, according to Novartis. Risk reduction was even greater at six months, but the announcement didn’t specify a percentage. The trial also revealed BAF312 caused a risk reduction in confirmed disability in predefined subgroups along with making a notable difference in annualized relapsed rates and percent change in brain volume and brain lesions.

The drug was comparable to rival candidates in this category demonstrating a profile that was generally safe and well tolerated.

Results from this study are still in its early stages, but they could bode well for Novartis.

“These data are a positive stride forward in an unserved disease area, and we look forward to evaluating next steps with health authorities,” said Novartis Chief Medical Officer Vasant Narasimhan to Reuters.

Certain analysts feel this treatment is an “under-appreciated” component in Novarts’s pipeline. It has a high chance of bringing in an estimated $3 billion in peak sales. Novartis plans to submit a regulatory filing sometime in 2019.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE